The Next Big BioTech Buyout?
Bold Stocks Newsletter
ARTH | Arch Therapeutics
Bandage Obsolete
Arch Therapeutics (ARTH) to unveil what can be among the most important medical discoveries in decades. And I expect this to propel ARTH shares 300 to 500 this year alone! Arch Therapeutics (ARTH) hit my ” buy list” when they announced their newly developed product, AC5™. This remarkable product stops a wound from bleeding in just seconds! It will be introduced to surgeons first… Then it could go global, a game-changer in a $ 32 billion marketplace for wound care products!
Fellow Investor:
The 100-year-old bandage may well be on its way to the back of the medicine chest.
Its potential replacement, a breakthrough in bleeding control developed at one of the world`s most respected medical research facilities…is entering final phases to market.
It may very well change everything we do about bleeding, starting in surgery.
Bleeding complications plague surgeons, doctors and patients, contributing to poor outcomes and longer hospital stays. AC5™ may be the best product ever developed for surgical bleeding control .
Outside the hospital, bleeding control is essential in trauma response, especially in the military where bleeding is the number one cause of battlefield deaths.
And for the first time in nearly a century, Moms have a new solution for routine scrapes and cuts that could render the common bandage obsolete!
This medical game-changer could be a huge growth opportunity for ARTH shareholders, especially if those that get in now.
As Arch Therapeutics moves into final testing prior to market release, ARTH shares are poised to soar. This may be your last chance to catch ARTH early. This is a strong buy I recommend you act on immediately! You can get ahead of the game by reading my new Arch Therapeutics report online now. It reveals how:
It is now entering human trials to regulatory approval , which is the pivotal point for ground floor investing…
Pre-clinical trials confirmed its efficacy with stunning results…
Arch Therapeutics gained exclusive licenses to the product from the Massachusetts Institute of Technology……
A stellar team of world-renown medical researchers, surgeons and medical products specialists are preparing to bring this product to market…
Surgeons are already calling this the “Holy Grail” that could be used in “80% of cases”…
Its European introduction should accelerate regulatory approvals to explosive growth in America…
And key to shareholders… This is the point when ARTH can jump to the buy list of biotech investors! With final phases of product trials and approvals underway, this may be a short-lived opportunity! A buy now can put you in front of a rush that could push ARTH to $3.00 to $5.00 this year.
300% to 500% gains on ARTH shares now trading around a dollar!
Don`t expect this opportunity to stick around much longer.
ARTH comes to market as one of the best biotech buys I`ve uncovered in my years of experience. Their product holds enormous global potential and could produce huge gains for ground-floor shareholders. Get all the details on this emerging story through my new report. I urge you to read it now!
Speed Retirement System Newsletter
Pentony Enterprises LLC “PE” – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031. PE received three thousand dollars for this advertisement. View Important Disclaimer Here
No related posts.